Avacopan

阿伐可泮

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameAvacopan
Drug Alias Nameavacopanum阿伐可泮avacopanTavneosVynpenta +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC5a anaphylatoxin chemotactic receptor antagonists
TargetsC5a anaphylatoxin chemotactic receptor
Therapy Area/IndicationsC3 glomerulopathyLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[11] 
Global Approved IndicationsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMicroscopic PolyangiitisGranulomatosis with Polyangiitis
Approved Indications in ChinaAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMicroscopic PolyangiitisGranulomatosis with Polyangiitis
Original Approved Country/TerritoryJapan
Original Approved Date2021/09/27
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChemocentryx
China Registration ClassN/A

Develop Information

Active CompaniesVifor Fresenius Medical Care Renal Pharma France Vifor SaChemocentryx IncAmgen Inc +[6] 
Inactive CompaniesChemocentryxVifor Fresenius Medical Care Renal Pharma LtdMario Negri Institute For Pharmacological Research
Active IndicationsC3 glomerulopathyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisKidney Failure, Chronic +[5] 
Inactive IndicationsLupus Erythematosus, SystemicVasculitisAtypical Hemolytic Uremic Syndrome +[6] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG